Skip to content

fat cells to fuel
health & longevity.

We’re pioneering disease-targeting therapies for obesity, liver disease and chronic inflammation by transforming white fat on a cellular level.


We’re reprogramming white fat into brown fat to combat serious, global diseases.

At MetaShape Pharma, our purpose is to help people live their best lives by turning back the clock on their fat cells. Our drug, MS 001, has the potential to be effective across a range of indications.

Graphic representing Obesity
Graphic representing Non-Alcoholic Steatohepatitis (NASH)
Non-Alcoholic Steatohepatitis (NASH)
Graphic representing Immune-Mediated Disease
Immune-Mediated Disease
Graphic representing Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Graphic representing Lower Urinary Tract Dysfunction
Lower Urinary Tract Dysfunction
Graphic representing Cancer-Related Obesity
Cancer-Related Obesity
Graphic of earth with fat cells and pills

Understanding the Nature of Fat Cells

Graphic of white fat cell

White Fat Cells
increase with age

Powerful endocrine organ
Cause high blood glucose & resistance to insulin
Raise cholesterol & risk of heart disease
Cause inflammation
Graphic of brown fat cell

Brown Fat Cells
decrease with age

Healthy type of body fat
Efficient at burning energy
Aid cardio-metabolic health
Control blood sugar

Discovering the Snowball Effect on Fat Transformation

A groundbreaking discovery published in the journal, Nature 1 2, has shown that when brown fat cells die, they release the purine nucleoside and signaling molecule inosine, which induces the “browning” of white adipose tissue via snowball kinetics. This information has provided us the missing link that has long prevented brown-fat therapies in succeeding.

1Article One
2Article Two

MS 001 Therapy Effectively Stimulates Reprogramming of White Fat Cells

MS 001 is an orally administered purine nucleoside phosphorylase (PNP) inhibitor that elevates very high levels of inosine, the key metabolite for transforming white fat into brown fat. MS 001 is proven to be a much more effective way to internally trigger cell transformation, as opposed to simply administering inosine.

graphic showing ms001 makeup

Explore How MS 001 Works at a Cellular Level


We’re disrupting the treatment of obesity.

More than 1 billion people worldwide are obese.

World Health Organization

It’s time to tackle the root cause of obesity with MS 001.

MS 001 Pre-Clinical Results on Obesity

MS 001 increases inosine signalling, which leads to browning of white fat. This transformation fires up energy consumption and shrinks body fat for:

  • Healthy and sustained weight loss.

In addition, MS 001:

  • Normalizes blood glucose
  • Lowers serum cholesterol
  • Reduces uric acid

MS 001 has been shown to be safe and well-tolerated in earlier Phase II human studies.

Photo of scientist looking into microscope

Broad Application for Future Growth

Our mode of action has applications in additional indications and risk-mitigated development pathways

illustration of our pipeline
About Us

Deep Experience in Pharmaceutical Science

Thomas Mehrling, MD, PhD
Chief Executive Officer
Shanta Bantia, PhD
Chief Scientific Officer
Jessica Kourniakti, DPhil
Chief Operating Officer
Randall Riggs, MBA
Chief Business Officer

Request Our One-Pager

MetaShape’s Trajectory and 5-Year Development Plan

Help us usher in this groundbreaking drug and improve the lives of millions.

Schedule a Call

Photo of Thomas Mehrling